Chromatographic purity does not constitute a toxicological safety profile.
In analytical peptide biochemistry, chromatographic purity is routinely conflated with biological safety. Empirical forensic testing of gray-market peptide supply chains reveals a consistent pattern: nominal product labeling frequently diverges from true vial composition, and non-target impurities remain uncharacterized.
Forensic analysis of secondary market formulations
In August 2026, the Australian Broadcasting Corporation (ABC) published analytical findings examining counterfeit and gray-market formulations of investigational multi-receptor peptides distributed via online storefronts, after reported cases of acute liver injury tied to those vials:
- Quantitative variance
- Of eighteen independent samples subjected to quantitative assay, only one conformed to its nominal label strength. The remaining seventeen demonstrated significant over- or under-concentration.
- Compositional discrepancy
- Target peptide mass accounted for approximately 10% of total solids in evaluated vials; the remaining 90% comprised uncharacterized secondary compounds and excipients.
- Documented harm
- The reporting described severe acute liver injury, including cases that reached transplant.
- Investigational status
- Investigational multi-receptor peptides remain unapproved chemical compounds without global marketing authorization. Consequently, any retail formulation sold as a finished product for personal use is unapproved and unvalidated by definition.
What identity and purity assays do not tell you
Standard commercial Certificates of Analysis generally report results from two analytical methodologies: reverse-phase high-performance liquid chromatography (RP-HPLC) for relative peak area integration, and electrospray ionization mass spectrometry (ESI-MS) for molecular mass verification.
“All that they know from this testing is that there is some target peptide in their vials. It doesn’t actually tell them if there’s any other contaminants or any other drugs or medications that could be mixed with them.”
Dr Marie Sinclair, transplant hepatologist, Austin Health, quoted by the ABC
“We had two different laboratories help us with that and did a very extensive analysis of components in these vials, and even with extensive testing we don’t have the full picture.”
Dr Marie Sinclair, on forensic screening of vials associated with acute toxicity
Optical RP-HPLC coupled with single-quadrupole ESI-MS remains blind to:
- Bacterial endotoxins
- Pyrogenic lipopolysaccharides (LPS) requiring specialized Limulus amebocyte lysate (LAL) or recombinant Factor C (rFC) fluorometric assays.
- Heavy metal catalysts
- Residual palladium, tin, or lead scavengers undetectable without inductively coupled plasma mass spectrometry (ICP-MS).
- Residual synthesis reagents
- Trace organic solvents (e.g., trifluoroacetic acid, dichloromethane, dimethylformamide, piperidine) requiring headspace gas chromatography-mass spectrometry (GC-MS).
- Microbial and fungal bioburden
- Viable particulate contamination undetectable without specialized compendial sterility cultures.
Scope of supplier analytical documentation
Lyotide Scientific provides batch-specific manufacturer CoAs to supply empirical baseline documentation for intake logging. This documentation does not confer a safety certification, nor does it clear material for in vivo applications.
- Certificate of analysis
- Empirical evidence of compound identity and relative optical purity for an individual manufacturing batch, derived under specified conditions at a specific time point.
- Exclusions
- A standard CoA is not a toxicological evaluation, sterility certification, endotoxin clearance, or validation for in vivo veterinary or human use.
- Commercial positioning
- We supply institutional and commercial enterprises strictly under a for research and development / laboratory use only (RUO) mandate.
- Internal release
- Enterprise clients are expected to subject all inbound raw materials to internal orthogonal analytical verification aligned with their specific experimental tolerances.
Related reading: research-use boundary, compounding regulatory landscape, and evaluating a peptide COA.
Carbonell, R., Gribbin, C., & Yu, A. (2026, August 28). ABC News (Australia). Read the original report. Quotations are the ABC’s; the commentary is ours.